2022E5SZEMNCT07893522

Understanding the Subnormal Rescue ofNeurological Development in Congenital Hypothyroidism (2022E5SZEM)

StatusRecruiting

PhaseNot specified

SponsorIstituto Giannina Gaslini

Primary completionDec 5, 2025

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

Oct 19, 2026 Study First Submitted

Endpoints

Primary

Genetic mechanisms associated with neurological and cognitive outcomes in patients with congenital hypothyroidism

Timeframe: At baseline

Association of epigenetic and metabolomic profiles with neurological and cognitive outcomes

Timeframe: At baseline; additional biological samples may be collected during the study, if required for validation of epigenetic findings

Arms and interventions

Congenital Hypothyroidism (CH)

Healthy Controls Matched for Age and Sex - CH

Mild Neonatal Hyperthyrotropinemia (MNH)

Healthy Controls - MNH

Sites

3 sites in 1 country

About this trial

Congenital hypothyroidism (CH) is a condition present at birth in which the thyroid gland does not produce enough thyroid hormones. These hormones are essential for normal brain development. Although early diagnosis through newborn screening and treatment with thyroid hormone help prevent serious learning difficulties, some children with CH may still experience difficulties with thinking, learning, or development. This study aims to understand why some children with CH do not achieve the expected level of neurological and cognitive development despite early treatment. The researchers will study 39 patients with CH and compare them with 39 similar individuals without the condition. They will also study 50 children with mild neonatal hyperthyrotropinemia (MNH), a condition involving mildly elevated thyroid-stimulating hormone levels, and compare them with 50 children without the condition. The study will assess medical information, growth measurements, and cognitive test results. Genetic testing will be used to identify changes in genes that may affect thyroid function or brain development. The researchers will also examine chemical changes that regulate how genes work, known as epigenetic changes, and analyze blood samples to identify differences in substances involved in the body's metabolism. By combining these findings, the study aims to identify factors associated with less favorable developmental outcomes and potential markers that may help identify children at risk. The results may improve understanding of congenital thyroid disorders and support earlier recognition of children who may need additional assessment or individualized care.

Trial details

Enrollment: 178 participants (estimated)
Started: Jun 20, 2024
Study completion: Dec 2026 (estimated)
Eligibility: 28 days and older, all sexes, no healthy volunteers
Design: Observational
Conditions: Congenital Hypothyroidism, Neurodevelopmental Disorders
Official title: Understanding the Subnormal Rescue ofNeurological Development in Congenital Hypothyroidism (Comprendere le Ragioni Dell'Incompleta Correzione Dei Difetti Dello Sviluppo Neurologico Nell'Ipotiroidismo Congenito)
First posted: Oct 26, 2026
Registry updated: Oct 26, 2026
Last verified: Oct 2026

Related trials at risk

View on ClinicalTrials.gov ↗